Gilead Sciences (NASDAQ:GILD) Insider Sells $3,524,080.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Johanna Mercier also recently made the following trade(s):

• On Wednesday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $118.08, for a total value of $354,240.00.
• On Monday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $113.57, for a total value of $340,710.00.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $3.09 during trading hours on Tuesday, hitting $127.18. The company’s stock had a trading volume of 8,175,751 shares, compared to its average volume of 7,956,847. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $127.68. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The business’s 50-day moving average is $117.61 and its two-hundred day moving average is $113.02. The company has a market capitalization of $157.79 billion, a PE ratio of 25.33, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the firm earned $2.02 EPS. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Needham & Company LLC increased their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $129.13.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors have recently modified their holdings of GILD. Trivium Point Advisory LLC boosted its position in Gilead Sciences by 1.1% during the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after acquiring an additional 83 shares during the last quarter. Binnacle Investments Inc raised its holdings in Gilead Sciences by 11.8% in the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 83 shares during the last quarter. Rothschild Investment LLC lifted its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after purchasing an additional 84 shares during the period. Hemington Wealth Management boosted its holdings in shares of Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 85 shares during the last quarter. Finally, Ignite Planners LLC grew its position in shares of Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.